Clinical trial
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis…
NCT00499590 · OPKO Health, Inc., Industry · Terminated
Key facts
| NCT number | NCT00499590 |
|---|---|
| Title | Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD |
| Official title | A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular… |
| Acronym | COBALT |
| Lead sponsor | OPKO Health, Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | bevasiranib, ranibizumab |
| Enrollment | 338 |
| Start date | Aug 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jul 11, 2007 |
| Last update posted | Oct 6, 2014 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: